Figure 2
From: Lack of a synergistic effect of a non-viral ALS gene therapy based on BDNF and a TTC fusion molecule
TTC and BDNF detection in skeletal muscle and spinal cord of ALS transgenic SOD1G93A mice. A. PCR amplification for the detection of TTC expression in mouse quadriceps extracts after intramuscular injections of TTC and BDNF-TTC plasmids. (1) TTC plasmid injected quadriceps extract; (2) BDNF-TTC-plasmid injected quadriceps extract; (3) molecular weight marker, MW; (4) positive control, C (vehicle or empty-plasmid-injected quadriceps extract); (5) reaction blank (n = 5 mice per group). B. Western blot detection of TTC in spinal cord and skeletal muscle tissues of wild-type (C-, negative control), SOD1G93A transgenic mice injected with empty plasmid (C+, positive control), TTC- and BDNF-TTC (BTTC)-treated mice. In TTC and BDNF-TTC treated groups, the detected band was approximately of 50 and ~ 70 KDa respectively (*), using both anti-TTC and anti-BDNF antibodies. In the BDNF group, the dimeric conformation, indicated by arrows, was observed at approximately 40 KDa (n = 5 mice per group).